Aktieanalys

Biovica Q4 2021/22: The Final Countdown - Redeye

{newsItem.title}

Redeye Publicerad: 16 Jun 2022 10:27

Biovica can point to significant progress lately. The FDA submission was cleared well before schedule, and DiviTum is securing additional scientific support, including the independent BioItaLEE study at ASCO related to Novartis CDK4/6i product.

Länk till analysen i sin helhet: https://www.redeye.se/research/846496/biovica-q4-2021-22-the-final-countdown?utm_source=finwire&utm_medium=RSS

Nyheter om Biovica

Läses av andra just nu

Om aktien Biovica

Senaste nytt